The stock of Kite Pharma Inc (NASDAQ:KITE) is a huge mover today! About 478,853 shares traded hands. Kite Pharma Inc (NASDAQ:KITE) has risen 12.31% since March 9, 2016 and is uptrending. It has outperformed by 4.90% the S&P500.
The move comes after 5 months negative chart setup for the $2.49B company. It was reported on Oct, 12 by Barchart.com. We have $49.82 PT which if reached, will make NASDAQ:KITE worth $124.50 million less.
Analysts await Kite Pharma Inc (NASDAQ:KITE) to report earnings on November, 10. They expect $-1.66 earnings per share, down 163.49% or $1.03 from last year’s $-0.63 per share. After $-1.31 actual earnings per share reported by Kite Pharma Inc for the previous quarter, Wall Street now forecasts 26.72% negative EPS growth.
Kite Pharma Inc (NASDAQ:KITE) Ratings Coverage
Out of 9 analysts covering Kite Pharma (NASDAQ:KITE), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Kite Pharma has been the topic of 22 analyst reports since August 4, 2015 according to StockzIntelligence Inc. On Friday, November 13 the stock rating was downgraded by Standpoint Research to “Hold”. The firm has “Buy” rating by Mizuho given on Tuesday, May 10. Vetr upgraded Kite Pharma Inc (NASDAQ:KITE) on Tuesday, August 4 to “Buy” rating. The stock has “Mkt Perform” rating given by FBR Capital on Friday, November 13. Guggenheim maintained the shares of KITE in a report on Friday, August 14 with “Buy” rating. Suntrust Robinson initiated Kite Pharma Inc (NASDAQ:KITE) on Friday, January 29 with “Buy” rating. The rating was initiated by Citigroup on Thursday, February 25 with “Buy”. The rating was upgraded by FBR Capital on Tuesday, January 19 to “Outperform”. The rating was maintained by Mizuho on Monday, August 17 with “Outperform”. The company was maintained on Sunday, August 16 by Stifel Nicolaus.
According to Zacks Investment Research, “Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.”
Insitutional Activity: The institutional sentiment increased to 1.57 in 2016 Q2. Its up 0.38, from 1.19 in 2016Q1. The ratio increased, as 23 funds sold all Kite Pharma Inc shares owned while 37 reduced positions. 23 funds bought stakes while 71 increased positions. They now own 36.34 million shares or 0.96% less from 36.69 million shares in 2016Q1.
Sg Americas Securities Ltd owns 84,746 shares or 0.03% of their US portfolio. Dai Ichi Life Comm Ltd accumulated 0.03% or 22,058 shares. Pictet Asset Management holds 0.04% or 183,643 shares in its portfolio. Blackrock Ltd Liability Corporation holds 0% or 46,323 shares in its portfolio. Blackrock Grp Limited has 29,587 shares for 0% of their US portfolio. Capital Fund Management Sa last reported 4,981 shares in the company. Cornerstone Ltd reported 4,765 shares or 0% of all its holdings. Price T Rowe Associates Md owns 239,742 shares or 0% of their US portfolio. Schwab Charles Invest Mgmt Inc owns 151,428 shares or 0.01% of their US portfolio. Mutual Of America Management holds 0.02% or 16,236 shares in its portfolio. Cap World holds 0.02% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 1.52M shares. Dekabank Deutsche Girozentrale has 142,950 shares for 0.08% of their US portfolio. Spot Trading Ltd Liability has 0% invested in the company for 2,133 shares. Citadel Advsr Ltd Co holds 0.01% of its portfolio in Kite Pharma Inc (NASDAQ:KITE) for 189,953 shares. Fmr Ltd Limited Liability Company, a Massachusetts-based fund reported 2.32M shares.
Insider Transactions: Since May 31, 2016, the stock had 0 buys, and 9 selling transactions for $2.93 million net activity. 10,000 shares were sold by BUTITTA CYNTHIA M, worth $541,300 on Monday, September 26. Another trade for 1,500 shares valued at $82,214 was sold by Wiezorek Jeffrey. Shares for $812,581 were sold by DOUMANI ROY on Monday, June 6.
More recent Kite Pharma Inc (NASDAQ:KITE) news were published by: Businesswire.com which released: “Kite Pharma to Host Investor Day on October 18, 2016 Spotlighting an Industry …” on October 11, 2016. Also Fool.com published the news titled: “How Kite Pharma Could Change Cancer Treatment Forever” on September 27, 2016. Marketwatch.com‘s news article titled: “Kite Pharma shares rally after study shows cancer drug benefit” with publication date: September 26, 2016 was also an interesting one.
KITE Company Profile
Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Firm offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Firm is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.